Minneapolis Portfolio Management Group LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Minneapolis Portfolio Management Group LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 272,894 shares of the medical equipment provider’s stock after purchasing an additional 8,780 shares during the period. Zimmer Biomet accounts for about 2.8% of Minneapolis Portfolio Management Group LLC’s portfolio, making the stock its 21st largest position. Minneapolis Portfolio Management Group LLC’s holdings in Zimmer Biomet were worth $24,539,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ZBH. Key Financial Inc increased its position in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $32,000. Grove Bank & Trust increased its position in Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Headlands Technologies LLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $37,000. Finally, Basepoint Wealth LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Stock Up 0.6%

ZBH stock opened at $82.83 on Tuesday. The firm has a 50 day moving average of $87.82 and a 200 day moving average of $90.61. The stock has a market capitalization of $16.02 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 1.90 and a beta of 0.48. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZBH. Citizens Jmp lowered their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. William Blair began coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They issued a “market perform” rating on the stock. Finally, BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.